Rodger J Elble1, Kelly E Lyons, Rajesh Pahwa. 1. Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL 62794-9643, USA. relble@siumed.edu
Abstract
OBJECTIVE: To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was titrated from 500 to 3000 mg/d during a 5-week titration phase, as tolerated, and the maximum tolerated dosage was then maintained for 4 weeks. There was a 3-week washout phase between the 2 treatment periods. Patients were assessed with the Fahn-Tolosa-Marín tremor rating scale (TRS), and tremor in the spiral and line drawings of 7 patients was quantified with a computerized digitizing tablet. Changes in other antitremor medications (10 patients) were not permitted during the study. RESULTS: The planned enrollment of 45 patients was stopped when an interim analysis of the first 15 patients revealed no efficacy. One patient failed to achieve the 3000-mg/d dosage of levetiracetam. Three patients dropped out of the study due to lack of efficacy and other side effects. The analysis of TRS data with these three patients excluded and after imputing their missing data (last value carried forward) revealed a statistically insignificant trend for all TRS and tablet measures to be worse when patients were taking levetiracetam. There was no period effect or treatment-period interaction for any measure of tremor. The results were the same for the 5 patients taking no other antitremor medications. CONCLUSIONS:Levetiracetam is not beneficial in the treatment of essential tremor.
RCT Entities:
OBJECTIVE: To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS: Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was titrated from 500 to 3000 mg/d during a 5-week titration phase, as tolerated, and the maximum tolerated dosage was then maintained for 4 weeks. There was a 3-week washout phase between the 2 treatment periods. Patients were assessed with the Fahn-Tolosa-Marín tremor rating scale (TRS), and tremor in the spiral and line drawings of 7 patients was quantified with a computerized digitizing tablet. Changes in other antitremor medications (10 patients) were not permitted during the study. RESULTS: The planned enrollment of 45 patients was stopped when an interim analysis of the first 15 patients revealed no efficacy. One patient failed to achieve the 3000-mg/d dosage of levetiracetam. Three patients dropped out of the study due to lack of efficacy and other side effects. The analysis of TRS data with these three patients excluded and after imputing their missing data (last value carried forward) revealed a statistically insignificant trend for all TRS and tablet measures to be worse when patients were taking levetiracetam. There was no period effect or treatment-period interaction for any measure of tremor. The results were the same for the 5 patients taking no other antitremor medications. CONCLUSIONS:Levetiracetam is not beneficial in the treatment of essential tremor.
Authors: T A Zesiewicz; R J Elble; E D Louis; G S Gronseth; W G Ondo; R B Dewey; M S Okun; K L Sullivan; W J Weiner Journal: Neurology Date: 2011-10-19 Impact factor: 9.910
Authors: Dietrich Haubenberger; Daniel Kalowitz; Fatta B Nahab; Camilo Toro; Dominic Ippolito; David A Luckenbaugh; Loretta Wittevrongel; Mark Hallett Journal: Mov Disord Date: 2011-06-28 Impact factor: 10.338
Authors: Dietrich Haubenberger; Giovanni Abbruzzese; Peter G Bain; Nin Bajaj; Julián Benito-León; Kailash P Bhatia; Günther Deuschl; Maria João Forjaz; Mark Hallett; Elan D Louis; Kelly E Lyons; Tiago A Mestre; Jan Raethjen; Maria Stamelou; Eng-King Tan; Claudia M Testa; Rodger J Elble Journal: Mov Disord Date: 2016-06-06 Impact factor: 10.338
Authors: Theresa A Zesiewicz; Jessica D Shaw; Kevin G Allison; Joseph S Staffetti; Michael S Okun; Kelly L Sullivan Journal: Curr Treat Options Neurol Date: 2013-08 Impact factor: 3.598
Authors: Rodger Elble; Cynthia Comella; Stanley Fahn; Mark Hallett; Joseph Jankovic; Jorge L Juncos; Peter Lewitt; Kelly Lyons; William Ondo; Rajesh Pahwa; Kapil Sethi; Natividad Stover; Daniel Tarsy; Claudia Testa; Ron Tintner; Ray Watts; Theresa Zesiewicz Journal: Mov Disord Date: 2012-10-02 Impact factor: 10.338
Authors: Mario Zappia; Alberto Albanese; Elisa Bruno; Carlo Colosimo; Graziella Filippini; Paolo Martinelli; Alessandra Nicoletti; Graziella Quattrocchi; Giovanni Abbruzzese; Alfredo Berardelli; Roberta Allegra; Maria Stella Aniello; Antonio E Elia; Davide Martino; Daniela Murgia; Marina Picillo; Giovanna Squintani Journal: J Neurol Date: 2012-08-11 Impact factor: 4.849